Author:
Eccles Diana M.,Balmaña Judith,Clune Joe,Ehlken Birgit,Gohlke Annegret,Hirst Ceri,Potter Danielle,Schroeder Claudia,Tyczynski Jerzy E.,Gomez Garcia Encarnacion B.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference80 articles.
1. Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–30.
2. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG). Diagnostik, Therapie und Nachsorge: Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG). 2013. http://www.awmf.org/uploads/tx_szleitlinien/032-035OLl_Maligne_Ovarialtumoren_Diagnostik_Therapie_Nachsorge_2013-06_1.pdf . Accessed 29 Jan 2014.
3. WHO and IARC. Hormonal contraception and Post-menopausal Hormonal therapy. 1999. vol. 72.
4. Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer. 2010;46(12):2275–84.
5. Cibula D, Widschwendter M, Majek O, Dusek L. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update. 2011;17(1):55–67.
Cited by
47 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献